Fluphenazine Im Injection Suppliers & Bulk Manufacturers
Available Forms: Long-Acting Intramuscular Injection
Available Strengths: 25 mg/mL
Reference Brands: Prolixin Decanoate(US); Fluphenazine Decanoate(EU)
Category:
Antipsychotropic Drugs
Fluphenazine IM injection is a typical antipsychotic that works by blocking dopamine D2 receptors in the brain, helping to reduce psychotic symptoms like hallucinations, delusions, and agitation. It is primarily used to treat schizophrenia and other chronic psychoses, especially in patients with poor medication adherence.
Fluphenazine IM Injection is available in Long-Acting Intramuscular Injection
and strengths such as 25 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Fluphenazine IM Injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Fluphenazine IM Injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Fluphenazine IM injection, available in both short-acting and long-acting (decanoate) formulations, is FDA-approved in the United States for the treatment of chronic schizophrenia. In the EU, it is approved in select markets under national procedures. Regulatory submissions must meet GMP standards, ensure accurate dosing for depot formulations, and include safety data addressing extrapyramidal symptoms and neuroleptic malignant syndrome. EU applications must align with local pharmacovigilance requirements and psychiatric labeling standards. For global buyers seeking dossier-ready Fluphenazine IM injections and to explore other dosage forms and suppliers, visit Pharmatradz.com — your reliable B2B pharma sourcing platform.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing